Report Details:
15 Companies Covered
100 Pages
Market Research Future (MRFR) has published a cooked research report on the “Mitral Valve (Stenosis & Regurgitation) Treatment Market” that contains information from 2019 to 2035.
The Mitral Valve (Stenosis & Regurgitation) Treatment Market is estimated to register a CAGR of 8.48% during the forecast period of 2024 to 2035.
MRFR recognizes the following companies as the key players in the Global Immuno-oncology assay Market— include Abbott, Bayer AG, Edwards Lifesciences Corporation, Artivion, Inc., Medtronic, Novartis AG, Teva Pharmaceutical Industries Ltd, Affluent Medical, Valcare Medical, Corcym Group.
Mitral Valve (Stenosis & Regurgitation) Treatment Market Highlights
The Mitral Valve (Stenosis & Regurgitation) Treatment Market is estimated to register a CAGR of 8.48% during the forecast period and is estimated to reach USD 16,527.07 Million by 2035.
The expanding global is a pathological condition where the mitral valve narrows, restricting blood flow from the left atrium to the left ventricle, often due to rheumatic fever or calcification. This can lead to fatigue, shortness of breath, and heart failure if left untreated. Mitral valve stenosis is affecting approximately 1 in 100,000 individuals in the U.S. It is more prevalent in developing nations, where access to antibiotics and healthcare is often limited. Technological innovation, favourable reimbursement policies, and expanding healthcare infrastructure in emerging markets are further boosting market growth. Collectively, these factors are contributing to the rising demand for effective mitral valve stenosis and regurgitation treatments globally.
HeartValveSurgery.com, a leading patient advocacy group, is collaborating with the Smidt Heart Institute at Cedars-Sinai and the Penn Medicine Heart and Vascular Center at the University of Pennsylvania Health System to launch “Mitral Valve Disease Awareness Week.” This global initiative aims to increase awareness about the health risks and treatment benefits of mitral valve disease. According to their data, 75% of patients are unaware of the condition and its associated dangers. This awareness campaign is expected to boost demand in the global mitral valve (stenosis and regurgitation) treatment market.
Segment Analysis
The Mitral Valve (Stenosis & Regurgitation) Treatment Market has been segmented based By Pathological Condition, By Etiology, By Treatment.
Based on product, the Mitral Valve (Stenosis & Regurgitation) Treatment Market has been segmented into Mitral Stenosis, and Mitral Regurgitation. The Mitral Regurgitation segment held the largest market in 2024, and the same segment is the fastest growing segment during the forecast period.
Mitral stenosis is a pathological condition where the mitral valve narrows, restricting blood flow from the left atrium to the left ventricle, often due to rheumatic fever or calcification. This can lead to fatigue, shortness of breath, and heart failure if left untreated.
Based on etiology, the mitral stenosis treatment market has been segmented into rheumatic mitral stenosis and calcified (non-rheumatic) mitral stenosis. The Calcified (non-rheumatic) Mitral Stenosis segment held the largest market in 2024 and the same segment is the fastest growing segment during the forecast period.
Rheumatic and calcified (non-rheumatic) mitral stenosis represents two separate but important segments of the global market for mitral stenosis treatment, each of which is influenced by particular clinical and demographic factors. While calcified mitral stenosis is increasingly affecting aging populations in developed countries, aided by technological advancements in diagnostics and transcatheter interventions, rheumatic mitral stenosis remains common in areas with a high burden of rheumatic fever and benefits from the expansion of minimally invasive procedures.
Based on treatment, the mitral stenosis treatment market has been segmented into medications and surgery. The surgery segment was further divided into mitral valve repair surgery, mitral valve replacement surgery, transcatheter balloon valvotomy, and transcatheter mitral valve repair & replacement. The Surgery segment held the largest market in 2024, and the same segment is the fastest-growing segment during the forecast period.
The surgery plays a pivotal role in fostering the growth of the global mitral stenosis treatment market by providing curative and definitive intervention for patients with significant valve narrowing. Surgeries, including mitral valve repair surgery, mitral valve replacement surgery, transcatheter balloon valvotomy, and transcatheter mitral valve repair & replacement, are frequently required when medications individually are not sufficient and also when disease progression leads to severe complications. Moreover, increasing clinical trials for the surgery along with medication to manage mitral stenosis are fueling market growth. Medications are significantly fueling the growth of the mitral stenosis treatment market through managing symptoms and disease progression control, particularly in patients who are unsuitable for surgery and adjunct surgical interventions. The drug classes for mitral stenosis include beta blockers, anticoagulants, and diuretics, which are majorly prescribed to regulate heart rate, prevent blood flow, and reduce fluid overload in patients. Furthermore, the increasing awareness about the treatment and early diagnosis of the disease propelled the adoption, making the medication segment dominant in the market.
Regional Analysis
The Mitral Valve (Stenosis & Regurgitation) Treatment Market accounted for USD 3,954.87 Billion in 2024 and is projected to grow at a CAGR of 8.48% during the forecast period. Global market is further segmented into North America, Europe, Asia-Pacific, South America, Middle East & Africa.
The North America Mitral Valve (Stenosis & Regurgitation) Treatment Market accounted for USD 6,750.71 Billion in 2024 and is projected to grow at a CAGR of 8.48% during the forecast period. Europe is further segmented into the US, and Canada.
The Mitral Valve (Stenosis & Regurgitation) Treatment Market in North America is mitral valve treatment landscape is changing dramatically, driven by the convergence of advanced medical technologies, rising patient demand for less invasive procedures, and a highly specialised clinical environment. Moreover, increasing geriatric population also fuels the demand for mitral valve treatment market.
Further, the treatment paradigm for mitral valve complications is changing dramatically, owing to advances in catheter-based and less invasive therapies. Abbott's TendyneTM transcatheter mitral valve implant received European CE Mark clearance in 2020, propelling Europe to the forefront of regulatory acceptance and early commercial adoption of TMVI.
Additionally, The Asia-Pacific mitral valve treatment environment is quickly shifting to minimally invasive procedures, driven by demographic increase, increasing procedural knowledge, and purposeful clinical objectives. The introduction of minimally invasive and transcatheter techniques. Rheumatic heart disease remains a major cause of mitral valve pathology in several areas of the region, even as degenerative illness becomes more widespread among the elderly.
Key Findings of the Study
- The Mitral Valve (Stenosis & Regurgitation) Treatment Market is expected to reach USD 16,527.07 Million by 2035, at a CAGR of 8.48% during the forecast period.
- The Asia Pacific region accounted for the fastest growth in the global market.
- Abbott, Bayer AG, Edwards Lifesciences Corporation, Artivion, Inc., Medtronic, Novartis AG, Teva Pharmaceutical Industries Ltd, Affluent Medical, Valcare Medical, Corcym Group are the key market players.